Title:
HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2022/234965
Kind Code:
A1
Abstract:
The present invention relates to an isoxazolidin-2-yl-substituted heteroaryl derivative and a pharmaceutical composition for cancer prevention or treatment, comprising the compound as an active ingredient. The compound exhibits high inhibitory activity against the wild type or mutants of at least one of ErbB2 and ErbB4 and thus can be useful for treating cancers in which ErbB2 and ErbB4 are expressed.
Inventors:
LEE YOUNHO (KR)
HWANG SEONAH (KR)
DO WOOMI (KR)
SHIM INSEOB (KR)
LEE HWA (KR)
SON JUNGBEOM (KR)
KIM NAMDOO (KR)
KIM SUNGHWAN (KR)
JUNG HONGRYUL (KR)
YOO JIHYE (KR)
HWANG SEONAH (KR)
DO WOOMI (KR)
SHIM INSEOB (KR)
LEE HWA (KR)
SON JUNGBEOM (KR)
KIM NAMDOO (KR)
KIM SUNGHWAN (KR)
JUNG HONGRYUL (KR)
YOO JIHYE (KR)
Application Number:
PCT/KR2022/005144
Publication Date:
November 10, 2022
Filing Date:
April 08, 2022
Export Citation:
Assignee:
VORONOI INC (KR)
VORONOIBIO INC (KR)
VORONOIBIO INC (KR)
International Classes:
C07D413/04; A61K31/506; A61K31/5377; A61K31/5386; A61P35/00; C07D413/14; C07D417/14; C07D471/04; C07D487/04
Foreign References:
| KR20200111644A | 2020-09-29 | |||
| KR20170066650A | 2017-06-14 | |||
| KR20110127119A | 2011-11-24 | |||
| US20030171374A1 | 2003-09-11 | |||
| US20170313714A1 | 2017-11-02 |
Other References:
NAT REV CANCER, vol. 7, 2007, pages 169 - 81
NATURE REVIEWS CLINICAL ONCOLOGY, vol. 17, 2020, pages 33 - 48
CLIN CANCER RES, vol. 25, 2019, pages 2033 - 2041
NATURE REVIEWS CLINICAL ONCOLOGY, vol. 17, 2020, pages 33 - 48
CLIN CANCER RES, vol. 25, 2019, pages 2033 - 2041
Attorney, Agent or Firm:
DANA PATENT LAW FIRM (KR)
Download PDF:
Previous Patent: DISPLAY APPARATUS AND CONTROL METHOD THEREFOR
Next Patent: METHOD FOR PURIFYING SOPHOROLIPID
Next Patent: METHOD FOR PURIFYING SOPHOROLIPID